Insulet price target raised to $325 from $317 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Insulet (PODD) to $325 from $317 and keeps an Overweight rating on the shares following a quarter and guidance the the firm thinks will “prove sufficient for most,” though positioning is “a bit tougher now.” The uplift from T2 label expansion is starting to play out as expected and there is “still plenty of runway,” so the firm would view any share weakness as a buying opportunity, the analyst tells investors.